SIEMENS

"They've reinvented relativity!"



Nuclear Medicine products Economically Engineered for managed care.

At Siemens we've always provided you with the technical edge . . . from the first Anger gamma camera to the ZLC auto correction circuitry of today's DIACAM and dual or triple head MULTISPECT. Now in an age of perceived product similarity we add the benefits of Economic Engineering, proof positive of our commitment to your future in the managed care environment of this decade and beyond!

- ***Software upgrades that increase your throughput revenue.***
- ***Sub-specialty accessories that expand your referral base.***
- ***Extended warranties that reduce your operating costs.***
- ***Dedicated Nuclear service that guarantees uptime.***

All of our Planar, SPECT and PET systems are designed to potentiate the value of your operations dollar by utilizing detector, gantry, soft and hardware technology guaranteed to maximize your investment and minimize your risk! Because, relatively speaking, it's a whole new world in health care.

Siemens Medical Systems

Nuclear Medicine Group

2501 Barrington Road

Hoffman Estates, IL 60195

Telephone: 708-304-7700

Siemens...
technology in caring hands

The anatomy of the CAPTUS™ 2000 begins with a powerful brain



High-resolution 800x600 SVGA graphics enhance displays of all programs, especially the full spectrum visible during all counting procedures.

Menu-driven applications programs perform Thyroid Uptake, Wipe Testing, Bio Assay, Blood Volume (I125 or Cr51), RBC Survival and Schilling Test (standard and Dicopac).

Program speed is enhanced with the use of track-ball addition to keyboard. (An optional mouse is available.)

Ease of patient approach is provided by the perfectly counter-balanced vertical column.

Flared collimator swivels 360 degrees on the detector arm and meets ANSI Standard N 44.3 for thyroid uptakes.

Immediate report printing with the supplied 80 column dot matrix, near letter quality printer.

Speed and accuracy in radioisotope quality assurance, quality control, wipe tests, purity measurements and clinical uses is accomplished with the built-in well detector system. FDA clearance has been received for clinical use.

Stability **and ease of maneuverability** are provided by the design of the sturdy base and stand with swivel locking casters to maximize positioning.

The power of the latest 486 processor technology is the heart of the new CAPTUS 2000 Thyroid Uptake System. Capintec has matched a high level MCA board and latest windows-based software with easy to use applications programs.

Wipe Testing is performed by the CAPTUS 2000 using an automated peak search identifying any nuclide contamination. A full package of lab test including dual isotope Schillings may be performed with a report printed on the attached printer. Bio Assay was never easier. All test results are saved as archived files for review at another time. For more information, please call (800) 631-3826 today.

CAPINTEC, INC.
6 Arrow Road
Ramsey, NJ USA 07446
Phone: (800) 631-3826
Fax: (201) 825-1336

Nippon Capintec Co., Ltd.
Chiyoda-ku, Tokyo 101 Japan
Phone: 81-33-864-8100
Fax: 81-33-864-8110

AccuSync™
DIAGNOSTIC MEDICAL INSTRUMENTS

The Finest Line of Cardiac Gates Available



For over fourteen years, Advanced Medical Research, now known as AccuSync Inc., has been serving the cardiac health care industry with the finest line of cardiac gates available in today's market.

Our dedication to service and commitment to provide you with a reliable product have built the reputation of our gates.

With a complete line of models available, you are able to choose the gate which best corresponds to your specific requirements.

The AccuSync 5L, our top model (featured at left) includes CRT monitor (visual) and Strip Chart Recorder (hard copy).

Model Specifications:

- Auto/Manual trigger control
- No delay
- ECG output
- Audio indicator
- Trigger pulse LED
- Isolation amplifier for patient safety
- Compatible with all computers

AccuSync models 5L, 6L and 1L are CSA and ETL (UL544) approved

AccuSync 3L ***AccuSync 6L*** ***AccuSync 1L*** ***AccuSync 4M***

Model	Strip Chart	CRT Monitor	HR/R-R Int	Trigger
5L	•	•	•	•
6L		•	•	•
1L	•		•	•
3L			•	•
4M				•

Accessory and optional products available:
The AccuAmp 5, the 5 lead system available for AccuSync 5L, 6L, and 1L, transmits information through fiber optic link. Patient cables, lead wires, and BNC cables available for AccuSync models.

AccuSync INC.
132 Research Drive • Milford CT 06460
Phone (203) 877-1610 • Fax (203)877-8972

AccuSync Inc. formerly known as Advanced Medical Research Corporation

Circle Reader Service No. 7

Florida

Join more than 8000 of your colleagues in celebrating the 41st Annual Meeting of the Society of Nuclear Medicine in Orlando Florida, June 5-8, 1994. Participate in the intensive educational program, review posters, discuss the most recent developments with colleagues, and join any of a host of much talked about extracurricular activities. Don't miss this opportunity to learn, mingle with your colleagues, and visit with the exhibitors.

ORLANDO

WELCOME TO

Refresher and state-of-the art continuing education courses in chemistry, physics, quality assurance, cardiovascular nuclear medicine, PET, SPECT and NMR will supply up-to-the-minute approaches and procedures for all clinical settings.

SCIENTIFIC PAPERS

This years presentation of over 1000 scientific papers and posters includes a distillation of the latest advancements and finest work achieved by outstanding scientists and physicians in the field of nuclear medicine. These papers, presented by the original authors, with over 30 subjects to choose from, will provide a unique opportunity for enhancing your knowledge or exploring new avenues in correlative areas of nuclear medicine. Ample time is allotted at these presentations for questions and discussions.

An extensive display of scientific posters and exhibits will augment the presentation.

TECHNOLOGIST PROGRAM

The ever-increasing importance of the role of the nuclear medicine technologist will be explored in our Technologist Program, and over 70 hours of clinical updates will provide chief and staff technologists with the latest in basic, intermediate, and advanced studies. This program will broaden expertise and enhance the technologist's contribution to nuclear medicine.

AUDIOVISUALS, BOOKS, JOURNALS

The Society of Nuclear Medicine is continuously adding to its library of audiovisuals, books, and other publications. A stop at the publications booth is well worth the time. Here you will find on display what the Society has to offer for year-round educational advancement. Networking opportunities and job referral boards are available at special locations throughout the meeting as well as membership information at our membership booth.

EXPOSITION

All the major manufacturers of nuclear medicine products and services more than 100 in all-will be on hand to explain and demonstrate the most technologically-advanced equipment. Several companies will present User Meetings to give an in-depth understanding of their products.

REGISTRATION

	Before May 6	After May 6
Physicians/Scientists		
Members	**$160.00**	**$180.00**
Nonmembers	**$255.00**	**$275.00**
Technologists		
Members	**$130.00**	**$150.00**
Nonmembers	**$255.00**	**$275.00**

If you need further information, please contact:

The Society of Nuclear Medicine
Department of Meeting Services
136 Madison Avenue
New York. N.Y. 10016-6760
(212) 889-0717
Fax:(212)545-0221

41st ANNUAL MEETING


Breakthrough in cancer detection...
ONCOSCINT® CR/OV
Satumomab Pendetide (1mg/2mL)
A diagnostic tool that can assist decision making in patients with colorectal or recurrent ovarian adenocarcinoma
Please see last page for brief summary of prescribing information.

ONCOSCINT® CR/OV

Satumomab Pendetide (1mg/2mL)

To enhance decision making in the management of patients with

The first monoclonal antibody-based in determining both the location and

Reveals malignancy with tumor-targeted accuracy—

specifically targets the cell-surface antigen, TAG-72, common to colorectal and ovarian adenocarcinomas,[1,2] making it possible—with the use of existing nuclear medicine equipment—to detect extrahepatic abdominal and pelvic lesions.[3,4]

Provides information beyond the scope of standard diagnostic modalities—when interpreted in conjunction with a review of information obtained from other appropriate tests

Found to be beneficial in these difficult situations:

- determining the source of a rising serum tumor marker in patients with an otherwise-negative workup[2,4,5]



- determining extrahepatic abdominal and pelvic involvement in patients thought to have isolated and resectable recurrence[2,4]



- differentiating disease from postsurgical or postradiation anatomic changes[4]

Please see last page for brief summary of prescribing information.



colorectal or recurrent ovarian cancer...

imaging agent effective extent of disease

Assists decision making in patient management[2-5]—

enhanced medical/surgical management in difficult colorectal[3,4] and recurrent ovarian cases.[2,5]

Excellent safety profile*—

with generally minor and transient side effects occurring in less than 4% of patients studied (most frequently reported: fever, chills and clinically insignificant changes in blood pressure).[2]

*See Adverse Reactions section of brief summary on following page.

For further information, please call 1-800-833-3533.

ONCOSCINT® CR/OV

Satumomab Pendetide (1mg/2mL)

Tumor-targeted cancer detection

OncoScint® CR/OV Kit (satumomab pendetide)

Kit for the Preparation of indium In 111 satumomab pendetide
For Intravenous Use Only
Brief summary of prescribing information

INDICATIONS AND USAGE

OncoScint® CR/OV-In (indium In 111 satumomab pendetide) is a diagnostic imaging agent that is indicated for determining the extent and location of extrahepatic malignant disease in patients with known colorectal or ovarian cancer. Clinical studies suggest that this imaging agent should be used after completion of standard diagnostic tests when additional information regarding disease extent could aid in patient management. The diagnostic images acquired with OncoScint® CR/OV-In should be interpreted in conjunction with a review of information obtained from other appropriate tests.

OncoScint® CR/OV-In is not indicated as a screening test for ovarian or colorectal cancer.

Administration of OncoScint® CR/OV-In may result in falsely elevated values from *in vitro* immunoassays, including tests for carcinoembryonic antigen (CEA) and CA 125. Because this interference may persist for months, the clinical laboratory should investigate for assay interference in patients who develop elevated CEA or CA 125 subsequent to imaging with OncoScint® CR/OV-In (see *Drug/Laboratory Test Interactions*).

Due to insufficient safety and efficacy data regarding repeat administration of this product, this imaging agent is limited to single use only.

CONTRAINDICATIONS

OncoScint® CR/OV-In (indium In 111 satumomab pendetide) should not be used in patients who are hypersensitive to this or any other product of murine origin or to indium In 111 chloride.

WARNINGS

Allergic reactions, including anaphylaxis, can occur in patients who receive murine antibodies. Although serious reactions of this type have not been observed in clinical trials after OncoScint® CR/OV-In (indium In 111 satumomab pendetide) administration, medications for the treatment of hypersensitivity reactions should be available during administration of this agent.

PRECAUTIONS

General The components of the kit are sterile and pyrogen free and contain no preservative. OncoScint® CR/OV-In (indium In 111 satumomab pendetide) should be used within 8 hours after radiolabeling. It is essential to follow the directions for preparation carefully and to adhere to strict aseptic procedures during preparation of the radiolabeled product.

Each OncoScint® CR/OV kit is a unit of use package. The contents of the kit are to be used only to prepare OncoScint® CR/OV-In; unlabeled OncoScint® CR/OV should NOT be administered directly to the patient. After radiolabeling with indium-111, the entire OncoScint® CR/OV-In dose must be administered to the patient for whom it was prescribed. **Reducing the dose of either component may adversely impact imaging results, and, therefore, is not recommended.**

The contents of the kit are not radioactive. However, after the indium In 111 chloride is added, appropriate shielding of OncoScint® CR/OV-In must be maintained. Care should be taken to minimize radiation exposure to patients and medical personnel, consistent with proper hospital and patient management procedures.

In addition, radiopharmaceuticals should be used only by physicians and other professionals who are qualified by training and experience in the safe use and handling of radionuclides.

Information for Patients Murine monoclonal antibodies are foreign proteins, and their administration can induce human anti-murine antibodies (HAMA). While limited data exist concerning the clinical significance of HAMA, the presence of HAMA may interfere with murine-antibody based immunoassays, could compromise the efficacy of diagnostic or therapeutic murine antibody-based agents, and may increase the risk of adverse reactions. For these reasons, patients should be informed that the use of this product could affect the future use of other murine-based products, including OncoScint® CR/OV-In, and should be advised to discuss prior use of murine-antibody based products with their physicians (see *Heterologous Protein Administration*).

Heterologous Protein Administration Murine monoclonal antibodies (MAbs) are heterologous proteins, and their administration can induce human anti-murine antibodies (HAMA).

OncoScint® CR/OV-In has been shown to induce HAMA to murine IgG after single administration in about 40% of patients in tumor imaging trials. HAMA levels became negative (undetectable or < 400 ng/mL) in approximately half of such patients at 4 to 12 months after infusion.

While limited data exist concerning the clinical significance of HAMA, detectable HAMA levels can alter the clearance and tissue biodistribution of MAbs. In patients who develop persistently elevated serum HAMA levels, the efficacy of diagnostic or therapeutic murine antibody-based agents may be compromised.

When considering the administration of OncoScint® CR/OV-In to patients who have previously received murine antibody-based products, physicians should be aware of the potential for HAMA to alter clearance and biodistribution. The quality or sensitivity of the imaging study may be compromised. Therefore, prior to administration of murine antibodies, including OncoScint® CR/OV-In, the physician should review the patient history to determine whether the patient has previously received such products.

Preliminary data are available from repeat-administration studies of OncoScint® CR/OV-In in 69 patients who have received 105 repeat doses. However, there are insufficient data to determine the safety and efficacy of this product after repeat administration (see ADVERSE REACTIONS).

Drug/Laboratory Test Interactions: The presence of HAMA in serum may interfere with two-site murine antibody-based immunoassays, including assays for carcinoembryonic antigen (CEA) and CA 125. When present, this interference generally results in falsely high values. If HAMA is known or suspected to be present, the clinical laboratory should be notified and appropriate measures taken to avoid this interference. These methods include the use of non-murine immunoassays, or HAMA removal by adsorption, blocking, or heat inactivation.

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic or mutagenic potential of OncoScint® CR/OV-In or to evaluate its effect on fertility in males or females.

Pregnancy Category C Animal reproduction studies have not been conducted with OncoScint® CR/OV-In. It is also not known whether OncoScint® CR/OV-In can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. OncoScint® CR/OV-In should not be administered to a pregnant woman unless, in the opinion of the physician, the information to be gained outweighs the potential risks. MAb B72.3 has been shown to react with fetal gastrointestinal tissues.

In general, examinations using radiopharmaceuticals in women of childbearing potential should be performed during the first few days (approximately 10) following the onset of menses.

Nursing Mothers and/or Lactating Women It is not known whether OncoScint® CR/OV-In is excreted in human milk and, if so, for how long. Because many drugs are excreted in human milk, caution should be exercised when OncoScint® CR/OV-In is administered to a nursing woman. OncoScint® CR/OV-In has not been administered to lactating females and therefore should not be administered to nursing mothers unless, in the opinion of the physician, the information to be gained outweighs the potential risk. In such cases, formula feedings should be substituted for breast feedings.

Pediatric Use The safety and effectiveness of OncoScint® CR/OV-In in children have not been established.

To assist decision making in the management of patients with colorectal or recurrent ovarian cancer...

ONCOSCINT® CR/OV

Satumomab Pendetide (1mg/2mL)

Effective in determining both the location and extent of disease

Please refer to complete prescribing information before using **OncoScint CR/OV.**

ADVERSE REACTIONS

After administration of over 500 single i.v. doses of OncoScint® CR/OV-In (indium In 111 satumomab pendetide) in clinical trials, adverse reactions were observed in less than 4% of patients. No deaths attributable to OncoScint® CR/OV-In administration were reported. The most common adverse reaction was fever, which occurred in less than 2% of patients. Other adverse reactions, each of which occurred in less than 1% of patients, are listed in order of decreasing frequency: chills, hypotension, hypertension, rash, pruritus, sweating, nausea, arthralgia, asthenia, chest pain, headache, hypothermia, pain, flushing, diarrhea, confusion, dizziness, nervousness, crying, and angioedema. Although causality was not determined, an isolated occurrence of reversible thrombocytopenia was observed in a patient who received OncoScint® CR/OV-In in clinical trials.

Additional adverse reactions after 105 repeat administrations of OncoScint® CR/OV-In in 69 patients included two reports of fever, one complaint of abdominal pain, and two cases of non-serious, readily reversible reactions characterized primarily by flank pain.

OVERDOSAGE

The maximum amount of OncoScint® CR/OV-In (indium In 111 satumomab pendetide) that can be safely administered has not been determined. In clinical trials, single doses of 20 mg of OncoScint® CR/OV-In were administered to 64 patients with various types of epithelial carcinomas; the type and frequency of adverse reactions at this dose were similar to those observed with lower doses.

DOSAGE AND ADMINISTRATION

The dose of OncoScint® CR/OV (satumomab pendetide) is 1 mg radiolabeled with 5 mCi of indium In 111 chloride. Each dose is administered intravenously over 5 minutes and should not be mixed with any other medication during its administration. The patient dose of the radiolabel should be measured in a dose calibrator prior to administration.

Each OncoScint® CR/OV kit is a unit dose package. After radiolabeling with indium-111, the entire OncoScint® CR/OV-In dose should be administered to the patients. **Reducing the dose of either component may adversely impact imaging results, and is, therefore, not recommended.**

HOW SUPPLIED

The OncoScint® CR/OV kit (NDC No. 0044-0579-01) for the preparation of indium-111 labeled OncoScint® CR/OV includes one vial containing 1 mg of satumomab pendetide per 2 mL of sodium phosphate buffered saline and one 2 mL vial of sodium acetate buffer solution, 0.5 *M*. These solutions are sterile and pyrogen free and contain no preservative. Each kit also includes one sterile 0.22 µm Millex® GV filter, prescribing information, and two identification labels.

U.S. Patent Nos. 4,671,958 and 4,741,900

Revised 12/30/92

References **1.** Nabi HA, Doerr RJ. Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. *Am J Surg.* 1992;163:448-456. **2.** Data on file. Cytogen Corporation, Princeton, NJ. **3.** Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. *Ann Surg.* 1991;118-124.**4.** Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy with ^{111}In-CYT-103 in the management of colorectal carcinoma: a comparison with computed tomography. *Radiology.* 1992;185:179-186. **5.** Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of ^{111}In-CYT-103 immunoscintigraphy in ovarian cancer. *Gynecol Oncol.* 1993; 48:285-292.

Manufactured by:
CYTOGEN Corporation
Princeton, New Jersey 08540

Distributed by:
Knoll Pharmaceutical Company
30 North Jefferson Road
Whippany, New Jersey 07981

04033-10/93 Printed in USA

COPROMOTED BY CYTOGEN
Knoll Pharmaceutical Company



Cardiolite fills in the gaps with the superior clarity of technetium

CARDIOLITE fills in information gaps to provide you with a complete clinical picture.

For identifying and localizing ischemia and infarction, CARDIOLITE provides you with much more. Through expanded uses, CARDIOLITE is the only single agent to provide perfusion *and* function information with gated wall motion or first pass.

CARDIOLITE fills in scheduling gaps, too. By uncoupling the time of injection from the time of imaging, patients can be stressed one after another, then imaged at any time... up to 4 hours after injection, eliminating camera downtime.

Get superior information and throughput. Fill in the gaps with CARDIOLITE.

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

Fills in the gaps...with clarity that lasts

DU PONT PHARMA
Radiopharmaceuticals

Please see next page for brief summary of prescribing information.

Brief Summary

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

FOR DIAGNOSTIC USE

DESCRIPTION: Each 5ml vial contains a sterile, non-pyrogenic, lyophilized mixture of:
Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate - 1.0mg
Sodium Citrate Dihydrate - 2.6mg
L-Cysteine Hydrochloride Monohydrate - 1.0mg
Mannitol - 20mg
Stannous Chloride, Dihydrate, minimum ($SnCl_2 \cdot 2H_2O$) - 0.025mg
Stannous Chloride, Dihydrate, ($SnCl_2 \cdot 2H_2O$) - 0.075mg
Tin Chloride (Stannous and Stannic) Dihydrate, maximum (as $SnCl_2 \cdot 2H_2O$) - 0.086mg

Prior to lyophilization the pH is 5.3-5.9. The contents of the vial are lyophilized and stored under nitrogen.

This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection.The pH of the reconstituted product is 5.5 (5.0-6.0). No bacteriostatic preservative is present.

The precise structure of the technetium complex is $Tc99m[MIBI]_6^+$ where MIBI is 2-methoxy isobutyl isonitrile.

INDICATIONS AND USAGE: CARDIOLITE, Kit for the preparation of Technetium Tc99m Sestamibi is a myocardial perfusion agent that is useful in the evaluation of ischemic heart disease. CARDIOLITE, Kit for the preparation of Technetium Tc99m Sestamibi is useful in distinguishing normal from abnormal myocardium and in the localization of the abnormality, in patients with suspected myocardial infarction, ischemic heart disease or coronary artery disease. Evaluation of ischemic heart disease or coronary artery disease is accomplished using rest and stress techniques.

CARDIOLITE, Kit for the preparation of Technetium Tc99m Sestamibi, is also useful in the evaluation of myocardial function using the first pass technique.

Rest-exercise imaging with Tc99m Sestamibi in conjunction with other diagnostic information may be used to evaluate ischemic heart disease and its localization.

In clinical trials, using a template consisting of the anterior wall, inferior-posterior wall and isolated apex, localization in the anterior or inferior-posterior wall in patients with suspected angina pectoris or coronary artery disease was shown. Disease localization isolated to the apex has not been established. Tc99m Sestamibi has not been studied or evaluated in other cardiac diseases.

It is usually not possible to differentiate recent from old myocardial infarction or to differentiate recent myocardial infarction from ischemia.

CONTRAINDICATIONS: None known.

WARNINGS: In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Precautions).

PRECAUTIONS:

GENERAL

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to the patients consistent with proper patient management.

Contents of the kit before preparation are not radioactive. However, after the Sodium Pertechnetate Tc99m Injection is added, adequate shielding of the final preparation must be maintained.

The components of the kit are sterile and non-pyrogenic. It is essential to follow directions carefully and to adhere to strict aseptic procedures during preparation.

Technetium Tc99m labeling reactions involved depend on maintaining the stannous ion in the reduced state. Hence, Sodium Pertechnetate Tc99m Injection containing oxidants should not be used.

Technetium Tc99m Sestamibi should not be used more than six hours after preparation.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation and support apparatus.

The most frequent exercise stress test endpoints, which resulted in termination of the test during controlled Tc99m Sestamibi studies (two-thirds were cardiac patients) were:

Fatigue	35%
Dyspnea	17%
Chest Pain	16%
ST-depression	7%
Arrhythmia	1%

Carcinogenesis, Mutagenesis, Impairment of Fertility

In comparison with most other diagnostic technetium labeled radiopharmaceuticals, the radiation dose to the ovaries (1.5rads/30mCi at rest, 1.2 rads/30mCi at exercise) is high. Minimal exposure (ALARA) is necessary in women of childbearing capability. (See Dosimetry subsection in DOSAGE AND ADMINISTRATION section.)

The active intermediate, $[Cu(MIBI)_4]BF_4$, was evaluated for genotoxic potential in a battery of five tests. No genotoxic activity was observed in the Ames, CHO/HPRT and sister chromatid exchange tests (all *in vitro*). At cytotoxic concentrations (≥ 20μg/ml), an increase in cells with chromosome aberrations was observed in the *in vitro* human lymphocyte assay. $[Cu(MIBI)_4]BF_4$ did not show genotoxic effects in the *in vivo* mouse micronucleus test at a dose which caused systemic and bone marrow toxicity (9mg/kg, > 600 × maximal human dose).

Pregnancy Category C

Animal reproduction and teratogenicity studies have not been conducted with Technetium Tc99m Sestamibi. It is also not known whether Technetium Tc99m Sestamibi can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There have been no studies in pregnant women. Technetium Tc99m Sestamibi should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Technetium Tc99m Pertechnetate is excreted in human milk during lactation. It is not known whether Technetium Tc99m Sestamibi is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in children below the age of 18 have not been established.

ADVERSE REACTIONS: During clinical trials, approximately 8% of patients experienced a transient metallic or bitter taste immediately after the injection of Technetium Tc99m Sestamibi. A few cases of transient headache, flushing and non-itching rash have also been attributed to administration of the agent. Cases of angina, chest pain, and death have occurred (See WARNINGS and PRECAUTIONS). The following adverse reactions have been rarely reported: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis in the wrist joint; and severe hypersensitivity, which was characterized by dyspnea, hypotension, bradycardia, asthenia and vomiting within two hours after a second injection of Technetium Tc99m Sestamibi.

DOSAGE AND ADMINISTRATION: The suggested dose range for I.V. administration in a single dose to be employed in the average patient (70kg) is:

370-1110MBq (10-30mCi)

The dose administered should be the lowest required to provide an adequate study consistent with ALARA principles (see also PRECAUTIONS).

When used in the diagnosis of myocardial infarction, imaging should be completed within four hours after administration.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. Radiochemical purity should be checked prior to patient administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Store at 15-25°C before and after reconstitution.

RADIATION DOSIMETRY: The radiation doses to organs and tissues of an average patient (70kg) per 1110MBq (30mCi) of Technetium Tc99m Sestamibi injected intravenously are shown in Table 4.

Table 4. Radiation Absorbed Doses from Tc99m Sestamibi

	Estimated Radiation Absorbed Dose			
	REST			
	2.0 hour void		4.8 hour void	
Organ	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.9
Gallbladder Wall	2.0	20.0	2.0	20.0
Small Intestine	3.0	30.0	3.0	30.0
Upper Large Intestine Wall	5.4	55.5	5.4	55.5
Lower Large Intestine Wall	3.9	40.0	4.2	41.1
Stomach Wall	0.6	6.1	0.6	5.8
Heart Wall	0.5	5.1	0.5	4.9
Kidneys	2.0	20.0	2.0	20.0
Liver	0.6	5.8	0.6	5.7
Lungs	0.3	2.8	0.3	2.7
Bone Surfaces	0.7	6.8	0.7	6.4
Thyroid	0.7	7.0	0.7	6.8
Ovaries	1.5	15.5	1.6	15.5
Testes	0.3	3.4	0.4	3.9
Red Marrow	0.5	5.1	0.5	5.0
Urinary Bladder Wall	2.0	20.0	4.2	41.1
Total Body	0.5	4.8	0.5	4.8
	STRESS			
	2.0 hour void		4.8 hour void	
Organ	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.8
Gallbladder Wall	2.8	28.9	2.8	27.8
Small Intestine	2.4	24.4	2.4	24.4
Upper Large Intestine Wall	4.5	44.4	4.5	44.4
Lower Large Intestine Wall	3.3	32.2	3.3	32.2
Stomach Wall	0.5	5.3	0.5	5.2
Heart Wall	0.5	5.6	0.5	5.3
Kidneys	1.7	16.7	1.7	16.7
Liver	0.4	4.2	0.4	4.1
Lungs	0.3	2.6	0.2	2.4
Bone Surfaces	0.6	6.2	0.6	6.0
Thyroid	0.3	2.7	0.2	2.4
Ovaries	1.2	12.2	1.3	13.3
Testes	0.3	3.1	0.3	3.4
Red Marrow	0.5	4.6	0.5	4.4
Urinary Bladder Wall	1.5	15.5	3.0	30.0
Total Body	0.4	4.2	0.4	4.2

Radiopharmaceutical Internal Dose Information Center, July 1990, Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, TN 37831, (615) 576-3449.

HOW SUPPLIED: Du Pont Radiopharmaceutical's CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi, is supplied as a 5ml vial in kits of two (2), five (5) and thirty (30) vials, sterile and non-pyrogenic.

Prior to lyophilization the pH is between 5.3-5.9. The contents of the vials are lyophilized and stored under nitrogen. Store at 15-25°C before and after reconstitution. Technetium Tc99m Sestamibi contains no preservatives. Included in each two (2) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each five (5) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each thirty (30) vial kit are one (1) package insert, thirty (30) vial shield labels and thirty (30) radiation warning labels.

The U.S. Nuclear Regulatory Commission has approved this reagent kit for distribution to persons licensed to use byproduct material pursuant to section 35.11 and section 35.200 of Title 10 CFR Part 35, to persons who hold an equivalent license issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.

Marketed by
Du Pont Radiopharmaceutical Division
The Du Pont Merck Pharmaceutical Co.
331 Treble Cove Road
Billerica, Massachusetts, USA 01862
For ordering Tel. Toll Free: 800-225-1572
All other business: 800-362-2668
(For International, call 617-350-9332)

513062 9/92 Printed in U.S.A.


When
pain
is a
moving
target

METASTRON®
(STRONTIUM-89 CHLORIDE INJECTION)

Simultaneously targets all sites of metastatic bone pain.

LONG-TERM PALLIATION IN ONE CONVENIENT DOSE.

- Palliation of pain demonstrated in the majority of patients.[1,2]
- One dose of Metastron provides pain relief for an average of up to 6 months.[1]
- As an adjunct to radiotherapy, 63.6% of patients receiving Metastron (10.8 mCi) had reduced pain at 6 months as compared to 35.0% of patients receiving placebo (n=42).[3]
- Preferentially incorporates into multiple sites of metastatic bone — the dose absorbed in metastatic deposits is approximately ten times that absorbed in normal bone marrow.[4,5]

ADJUNCTIVELY DELAYS THE MEDIAN TIME TO PROGRESSION OF PAIN BY 28.1 WEEKS OVER RADIOTHERAPY ALONE.

Median time to requirement for additional radiotherapy at new pain site.[3]



From a multicenter, double-blind study of 126 patients who received a single injection of either Metastron 400 MBq, 10.8 mCi or placebo with fractionated doses of local field radiotherapy (20-30 Gy).

HIGHLY EFFECTIVE NON-NARCOTIC THERAPY.

- Metastron may reduce or eliminate the need for dose escalation of narcotic analgesics.[1,3]
- Onset of pain relief is generally within 7 to 20 days — Metastron is therefore not recommended in patients with very short life expectancy.

GENERALLY WELL TOLERATED.

- A depression of white blood cell (20%) and platelet (30%) levels may occur in patients treated with Metastron — clinically significant toxicity is rare.
- Metastron should be used with caution in patients with significantly compromised bone marrow from previous treatment. Caution should also be used in patients with platelet counts below 60,000 or white blood cell counts below 2,400.
- Some patients have reported a transient increase in bone pain lasting 36 to 72 hours following an injection — this can usually be controlled with analgesics.

AN IMPROVED QUALITY OF LIFE FOR PATIENTS.

- Metastron may improve patient quality of life, as measured by assessments of mood, mobility, appetite, sleep pattern, and analgesic consumption.[1-4]

Please see following page for full prescribing information.

METASTRON®
(STRONTIUM-89 CHLORIDE INJECTION)

An effective way to manage metastatic bone pain.

METASTRON®
(STRONTIUM-89 CHLORIDE INJECTION)

An effective way to manage metastatic bone pain.

Consult your radiation safety officer for product availability or call Amersham Healthcare/ Medi-Physics Technical Services at 1-800-554-0157.

Metastron® (Strontium-89 Chloride Injection)

Description: Metastron is a sterile, non-pyrogenic, aqueous solution of Strontium-89 Chloride for intravenous administration. The solution contains no preservative.

Each milliliter contains:		
	Strontium Chloride	10.9 - 22.6 mg
	Water for Injection	q.s. to 1 mL

The radioactive concentration is 37 MBq/mL, 1 mCi/mL and the specific activity is 2.96 - 6.17 MBq/mg, 80-167 µCi/mg at calibration. The pH of the solution is 4 - 7.5.

Physical Characteristics: Strontium-89 decays by beta emission with a physical half-life of 50.5 days. The maximum beta energy is 1.463 MeV (100%). The maximum range of ß- from Strontium-89 in tissue is approximately 8 mm.

Radioactive decay factors to be applied to the stated value for radioactive concentration at calibration, when calculating injection volumes at the time of administration, are given in Table 1.

Table 1: Decay of Strontium-89

Day*	Factor	Day*	Factor	Day*	Factor	Day*	Factor
-24	1.39	-12	1.18	+6	0.92	+18	0.78
-22	1.35	-10	1.15	+8	0.90	+20	0.76
-20	1.32	-8	1.12	+10	0.87	+22	0.74
-18	1.28	-6	1.09	+12	0.85	+24	0.72
-16	1.25	-4	1.06	+14	0.83	+26	0.70
-14	1.21	-2	1.03	+16	0.80	+28	0.68
		0 = calibration	1.00				

*Days before (-) or after (+) the calibration date stated on the vial.

Clinical Pharmacology: Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Strontium-89 Chloride is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones.

Excretion pathways are two-thirds urinary and one-third fecal in patients with bone metastases. Urinary excretion is higher in people without bone lesions. Urinary excretion is greatest in the first two days following injection.

Strontium-89 is a pure beta emitter and Strontium-89 Chloride selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Mean absorbed radiation doses are listed under the **Radiation Dosimetry** section.

Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred. In a multi-center Canadian placebo-controlled trial of 126 patients, pain relief occurred in more patients treated with a single injection of Metastron than in patients treated with an injection of placebo. Results are given in the following tables.

Table 2 compares the percentage and number of patients treated with Metastron or placebo who had reduced pain and no increase in analgesic or radiotherapy re-treatment.

Table 2: Comparison of the effects of Strontium-89 and placebo, as adjunct to radiotherapy, on treatment outcome over time.

	Months Post-Treatment					
	1	2	3	4	5	6
Metastron	71.4% (n=42)	78.9% (n=38)	60.6% (n=33)	59.3% (n=27)	36.4% (n=22)	63.6% (n=22)
Placebo	61.4% (n=44)	57.1% (n=35)	55.9% (n=34)	25.0% (n=24)	31.8% (n=22)	35.0% (n=20)

At each visit, treatment success, defined as a reduction in a patient's pain score without any increase in analgesic intake and without any supplementary radiotherapy at the index site, was more frequent among patients assigned to Metastron than to placebo.

Table 3 compares the number and percentage of patients treated with Metastron or placebo as an adjunct to radiotherapy who were pain free without analgesic at the intervals shown.

Table 3: Comparison of the effects of Strontium-89 and placebo, as adjunct to radiotherapy, on reduction of pain score and analgesic score to zero.

	Months Post-Treatment						
	1	2	3	4	5	6	9
Metastron	6	5	5	3	4	4	2
	14.3%	13.2%	15.2%	11.1%	18.2%	18.2%	18.2%
	(n=42)	(n=38)	(n=33)	(n=27)	(n=22)	(n=22)	(n=11)
Placebo	3	3	2	0	1	1	0
	6.8%	8.6%	5.9%		4.5%	5%	
	(n=44)	(n=35)	(n=34)	(n=24)	(n=22)	(n=20)	(n=17)

The number of patients classified at each visit as treatment successes who were pain free at the index site *and* required no analgesics was consistently higher in the Metastron group.

New pain sites were less frequent in patients treated with Metastron.

In another clinical trial, pain relief was greater in a group of patients treated with Metastron compared with a group treated with non-radioactive strontium-88.

Indications and Usage: Metastron (Strontium-89 Chloride Injection) is indicated for the relief of bone pain in patients with painful skeletal metastases.

The presence of bone metastases should be confirmed prior to therapy.

Contraindications: None known.

Warnings: Use of Metastron in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected following the administration of Metastron, particularly white blood cells and platelets. The extent of toxicity is variable. It is recommended that the patient's peripheral blood cell counts be monitored at least once every other week. Typically, platelets will be depressed by about 30% compared to pre-administration levels. The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Metastron. White blood cells are usually depressed to a varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration levels six months after treatment unless the patient's disease or additional therapy intervenes.

In considering repeat administration of Metastron, the patient's hematologic response to the initial dose, current platelet level and other evidence of marrow depletion should be carefully evaluated.

Verification of dose and patient identification is necessary prior to administration because Metastron delivers a relatively high dose of radioactivity.

Metastron may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

Precautions: Metastron is not indicated for use in patients with cancer not involving bone. Metastron should be used with caution in patients with platelet counts below 60,000 and white cell counts below 2,400.

Radiopharmaceuticals should only be used by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Metastron, like other radioactive drugs, must be handled with care and appropriate safety measures taken to minimize radiation to clinical personnel.

In view of the delayed onset of pain relief, typically 7 to 20 days post injection, administration of Metastron to patients with very short life expectancy is not recommended.

A calcium-like flushing sensation has been observed in patients following a rapid (less than 30-second injection) administration.

Special precautions, such as urinary catheterization, should be taken following administration to patients who are incontinent to minimize the risk of radioactive contamination of clothing, bed linen and the patient's environment.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Data from a repetitive dose animal study suggests that Strontium-89 Chloride is a potential carcinogen. Thirty-three of 40 rats injected with Strontium-89 Chloride in ten consecutive monthly doses of either 250 or 350 µCi/kg developed malignant bone tumors after a latency period of approximately 9 months. No neoplasia was observed in the control animals. Treatment with Strontium-89 Chloride should be restricted to patients with well documented metastatic bone disease.

Adequate studies with Strontium-89 Chloride have not been performed to evaluate mutagenic potential or effects on fertility.

Pregnancy: Teratogenic effects.

Pregnancy Category D. See **Warnings** section.

Nursing Mothers: Because Strontium acts as a calcium analog, secretion of Strontium-89 Chloride into human milk is likely. It is recommended that nursing be discontinued by mothers about to receive intravenous Strontium-89 Chloride. It is not known whether this drug is excreted in human milk.

Pediatric Use: Safety and effectiveness in children below the age of 18 years have not been established.

Adverse Reactions: A single case of fatal septicemia following leukopenia was reported during clinical trials. Most severe reactions of marrow toxicity can be managed by conventional means.

A small number of patients have reported a transient increase in bone pain at 36 to 72 hours after injection. This is usually mild and self-limiting, and controllable with analgesics. A single patient reported chills and fever 12 hours after injection without long-term sequelae.

Dosage and Administration: The recommended dose of Metastron is 148 MBq, 4 mCi, administered by slow intravenous injection (1-2 minutes). Alternatively, a dose of 1.5 - 2.2 MBq/kg, 40-60 µCi/kg body weight may be used.

Repeated administrations of Metastron should be based on an individual patient's response to therapy, current symptoms, and hematologic status, and are generally not recommended at intervals of less than 90 days.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Radiation Dosimetry: The estimated radiation dose that would be delivered over time by the intravenous injection of 37 MBq, 1 mCi of Strontium-89 to a normal healthy adult is given in Table 4. Data are taken from the ICRP publication "Radiation Dose to Patients from Radiopharmaceuticals"-ICRP #53, Vol. 18 No. 1-4, Page 171, Pergamon Press, 1988.

Table 4: Strontium-89 Dosimetry

Organ	mGy/MBq	rad/mCi	Organ	mGy/MBq	rad/mCi
Bone Surface	17.0	63.0	Testes	0.8	2.9
Red Bone Marrow	11.0	40.7	Ovaries	0.8	2.9
Lower Bowel Wall	4.7	17.4	Uterine Wall	0.8	2.9
Bladder Wall	1.3	4.8	Kidneys	0.8	2.9

When blastic osseous metastases are present, significantly enhanced localization of the radiopharmaceutical will occur with correspondingly higher doses to the metastases compared with normal bones and other organs.

The radiation dose hazard in handling Strontium-89 Chloride injection during dose dispensing and administration is similar to that from phosphorus-32. The beta emission has a range in water of about 8 mm (max.) and in glass of about 3 mm, but the bremsstrahlung radiation may augment the contact dose.

Measured values of the dose on the surface of the unshielded vial are about 65 mR/minute/mCi.

It is recommended that the vial be kept inside its transportation shield whenever possible.

How Supplied: Metastron is supplied in a 10 mL vial containing 148 MBq, 4 mCi. The vial is shipped in a transportation shield with approximately 3 mm lead wall thickness, package insert, and two therapeutic agent warning labels.

The vial and its contents should be stored inside its transportation container at room temperature (15-25° C, 59-77° F).

The calibration date (for radioactivity content) and expiration date are quoted on the vial label. The expiration date will be 28 days after calibration. Stability studies have shown no change in any of the product characteristics monitored during routine product quality control over the period from manufacture to expiration.

This radiopharmaceutical is licensed by the Illinois Department of Nuclear Safety for distribution to persons licensed pursuant to 32 Illinois Adm. Code 330.260 (a) and Part 335 Subpart F.335.5010 or under equivalent licenses of the USNRC or an Agreement State.

THIS PRODUCT INFORMATION ISSUED JUNE, 1993. Product Code: SMS.2PA

Manufactured by: **Amersham International plc**, Amersham, England

Medi-Physics, Inc.
2636 S. Clearbrook Drive
Arlington Heights, Illinois 60005

References:

1. Data on file, Amersham International plc, Amersham, England. 2. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer*. 1991;27:954-958. 3. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys*. 1993;25:805-813. 4. Blake GM, Zivanovic MA, McEwan AJ, et al. "Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. *Eur J Nucl Med*. 1987;13:41-46. 5. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. *Eur J Nucl Med*. 1986;12:447-454.

Amersham Healthcare
2636 S. Clearbrook Drive
Arlington Heights, IL 60005

ZENECA
Pharmaceuticals
A Business Unit of ZENECA Inc.
Wilmington, Delaware 19897 USA

Amersham **HEALTHCARE**

AHC94001 3200-0169 FSA-1803 194 Printed in U.S.A. 1/94

IN A FOG??

using aerosols to determine the patency of the pulmonary airway system? Use a gas (that's what the airway system is for), and Xenon (127 or 133) are gases which are safe, economical and easy to administer with the XENAMATIC™ 3000.

- Shielded for Xe 127 and Xe 133 (radiation profile available on request).
- World's only system that allows you to study patients on Ventilators.
- Largest and most efficient Xenon trap with a built-in monitor alarm system.
- Built-in O_2 monitor with digital display and control.
- A rebreathing system that saves Xenon.
- Low breathing resistance so you can study sick patients.
- Semi-automatic operation.
- Remote Control Capability.



Get out of the FOG-making business, and call today for more information on putting gases where gases belong, with the XENAMATIC.

Also available, Model 2000.

For more information, please call or write,

Circle Reader Service No. 32

DIVERSIFIED DIAGNOSTIC PRODUCTS, INC.
11603 Windfern
Houston, TX 77064
713-955-5323

CONTINUING MEDICAL EDUCATION IS THE PRIMARY FOCUS OF THE SOCIETY OF NUCLEAR MEDICINE'S 41ST ANNUAL MEETING

JUNE 5-8, 1994 • ORLANDO, FLORIDA

The 41st Annual Meeting of The Society of Nuclear Medicine will be held in Orlando, Florida, on Sunday, June 5 through Wednesday, June 8, 1994. Most of the educational activities for this meeting will be held at the Orange County Convention Center .

CONTINUING EDUCATION ACTIVITIES

A primary focus for every SNM Annual Meeting is the Continuing Education activities offered for physicians, scientists, pharmacists, and technologists.

This year we are pleased to offer 12 categorical seminars and 47 continuing education courses. There will also be a Nuclear Medicine Review Course geared toward nuclear medicine residents preparing for the ABNM boards and practitioners who wish to refresh their knowledge of nuclear medicine.

All categorical seminars will take place on Saturday, June 4 from 8:30 a.m. - 2:30 p.m. All other continuing education sessions will occur over the course of the meeting.

Once again, continuing medical education credits will be offered along with VOICE credits for technologist programs. The Scientific and Teaching Sessions Committee invites all physicians to participate.

The Society of Nuclear Medicine is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

The Society of Nuclear Medicine is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

Technologist section courses are approved for continuing education credit by the Technologist section of The Society of Nuclear Medicine under the criteria and guidelines established by the Council on the Continuing Education Unit.

TECHNICAL EXHIBITS

Another important component of the meeting is the technical exhibition, where the most advanced products and services for the nuclear medicine practitioner will be displayed. Attendees will have the opportunity to speak with technical experts and to see demonstrations of new equipment in an atmosphere free from the pressures of their busy practices.

Suppliers to the nuclear medicine community traditionally take advantage of the Society's Annual Meeting to showcase innovations developed over the past year and to introduce new products. They make a great effort to impress and influence their most important customers—our attendees.

This year will be no different: several long-time exhibitors have increased their space, and we anticipate an even larger show with more exhibitors than 1993's record-breaking meeting.

SPECT BRAIN IMAGING PRACTICA

Once again, the Brain Imaging Council will be offering a hands-on brain SPECT workshop for physicians desiring to optimize their practice and interpretative skills in this area. Three of the sessions will be allotted to beginners and three to experienced workers in the field. Because of its popularity, early enrollment is advised to avoid disappointment. Please Note: Admission to the advanced course requires previous attendance of the practica offered in the past two years or this year's basic course. Please refer to the 41st Annual Meeting Preview for registration instructions or call the SNM Department of Meeting Services.

For further information contact:
The Society of Nuclear Medicine
Department of Meeting Services
136 Madison Avenue
New York, NY 10016-6760
212-889-0717
FAX: 212-545-0221

Each description of the products below was condensed from information supplied by the manufacturer. The reviews are published as a service to the professionals working in the field of nuclear medicine and their inclusion herein does not in any way imply an endorsement by the Editorial Board of *The Journal of Nuclear Medicine* or by The Society of Nuclear Medicine.

Ultrasound Table



Combining Trendelenburg and Fowler back positioning, the Deluxe Ultrasound Table from Biodex is completely adjustable for a variety of imaging procedures. The table features three main positions: horizontal, chair and Trendelenburg and will lock firmly in whatever position is chosen. Accessories include retractable guard rails, adjustable stirrups and a detachable i.v. rod. Effortlessly adjustable, the table's height is controlled by a simple hydraulic foot pump to achieve proper height when loading or unloading the patient. Once the patient is comfortably positioned, it may be raised or lowered to the proper scanning height. Patient comfort is assured with a two-inch thick table pad, providing comfort throughout lengthy procedures. Two adjustable hook- and loop-fastened straps are included for added patient comfort and stability. **Biodex Medical Systems, Box 702, Shirley, NY 11967-0702. (516) 924-9000. Fax: (516) 924-9241.**

Photomultiplier Tube Base

A new photomultiplier tube base from EG&G Ortec makes high-voltage supplies obsolete. The new ScintiPack™ includes everything needed for NaI(Tl) detectors in one compact package: a high-voltage supply, an active bias network, a spectroscopy preamplifier and an anode output for timing. The internal bias supply eliminates bulky external high-voltage supplies and permits the entire tube base to operate at the unusually low power of 240 mW. The low power consumption coupled with the convenience of a single cable connection between ScintiPack and the shaping amplifier makes this PMT base ideal for portable applications. Due to the active bias network, ScintiPack excels at high counting rates. ScintiPack fits scintillation detectors that utilize a standard, ten-stage photomultiplier tube with a 14-pin tube base. **EG&G Ortec Nuclear Instruments, 100 Midland Rd., Oak Ridge, TN 37831-0895.**

New Safety Products Brochure

All of the Nalge Company's products designed and manufactured to help technicians avoid accidents and hazards in the lab are featured in the new six-page Nalgene™ safety products brochure. The products featured all comply with OSHA standard 29 CFR Part 1910.1030 for use as protection against bloodborne pathogens; Nalgene Right-To-Know labels and bottles for storing and identifying hazardous chemicals (they meet the requirements of OSHA Hazard Communication Regulation 29 CFR 1910.1210 [f]); beta and gamma radiation products for working with materials that emit those radioisotopes; safety and face shields to protect users from splashes and flying debris; as well as other products made with plastic resins to avoid breakage in the lab. A free copy of the brochure may be obtained by contacting the company. **Nalge Company, P.O. Box 20365, Rochester, NY 14602. (716) 264-3985. Fax: (716) 586-8431.**

New Diagnostic Imager Available

The 3M Model 969 HQ Laser Imager System is available from 3M Medical Imaging Systems. The new laser imager is the first black-and-white diagnostic imager to use new 3M Instant Daylight Load Film Cartridges and features a built-in automatic image quality control system. The Model 969 consists of a laser imager and a dedicated film processor which eliminates the need for a darkroom when used with 3M Instant Daylight Film Cartridges. Additionally, each film cartridge has a bar code that allows the imager to automatically adjust for film size and supply, as well as sensitometric data. The Model 969 also uses a built-in densitometer that reviews printed images and adjusts contrast, density, laser intensity and other variables that may affect image quality. This system automatically assures consistent, reliable image quality from sheet to sheet. The new system can accommodate up to eight modalities in any digital or analog configuration and can accept data from two consoles per modality and allows each user to independently select contrast, density and other parameters. The system also features a keypad and control panel that offers touch control for menu scrolling and feature selection and an optimal foot switch is also available. **3M Medical Imaging Systems, 3M Center Bldg., St. Paul, MN 55144-1000.**

Manual TLD Reader

Teledyne Isotopes has released the latest in its line of TLD products, the System 310 Manual Reader. Designed for use in demanding research and laboratory applications, the System 310 processes all TLD materials, including chips, rods, discs and powders. The system is low-maintenance and user-friendly and offers a variety of unique features such as: displayed and digitized glow curve and temperature file, unlimited configuration profile setting and storage, calibration for any unit of measurement, verification for a built-in quality control check and simple and accurate analysis. Additional features include an electronic LED reference light source for real time PMT drift correction, glow curve manipulation by adjusting integration set points for ROIs, element correction factor storage and automatic call-up, and an ASCII file translation for data output of all analysis components. The system 310 requires only an IBM or compatible PC that operates in Windows™. **Teledyne Isotopes, 50 Van Buren Ave., P.O. Box 1235, Westwood, NJ 07675-1235.**

Classified Advertising

Policy—*The Journal of Nuclear Medicine* accepts classified advertisements from medical institutions, groups, suppliers, and qualified specialists in nuclear medicine. Acceptance is limited to Positions Open, Positions Wanted, and Equipment. We reserve the right to decline, withdraw, or modify advertisements.

Rates for Classified Listings—$22.00 per line or fraction of line (approx. 50 characters per line, including spaces). Please allow 28 characters for the first line which will appear in capital letters. Special rates for SNM members on Positions Wanted. $10.00 per line. *Note: Box numbers are available for the cost of the 2 lines required.*

Rates for Display Ads—Agency commissions are offered on display ads only

Full page	$1500	Quarter page	$700
Half Page	950	Eighth page	550

Publisher-Set Charges—Page $150; half page $100; quarter page $75; eighth page $50.

Terms—Payment must accompany order. Make checks payable, in U.S. dollars on U.S. banks only, to: The Society of Nuclear Medicine.

Deadline—First of the month preceding the publication date (January 1 for February issue). Please submit classified listings typed double spaced. No telephone orders are accepted.

Send Copy to:

Classified Advertising Department
The Society of Nuclear Medicine
136 Madison Avenue
New York, NY 10016-6760
(212) 889-0717
FAX: (212) 545-0221

Positions Available

Fellowship

PEDIATRIC NUCLEAR MEDICINE FELLOWSHIP position in 270-bed preeminent pediatric center that conducts 2,800 imaging procedures per year encompassing all aspects of nuclear medicine with emphasis on teaching and research. Staff includes three full-time ABNM, ABR-certified practitioners. Four state-of-the-art gamma cameras and image processing and display system with networking. Salary 30-45K per annum. ABNM/ABR eligibility or certification required. Contact: James J. Conway, MD, The Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL 60614. (312) 880-4416.

Physician

NUCLEAR MEDICINE PHYSICIAN. Northern California–The Kaiser Permanente Medical Center in Santa Clara, CA is seeking a BC/BE Nuclear Medicine physician for a career opportunity with the nation's leading HMO. All aspects of nuclear medicine services are provided to a 250,000 member prepaid patient population. The ideal candidate should have experience in clinical management of thyroid disease and the performance of treadmill tests. Board certification/eligibility in internal medicine is preferred. Academic opportunities are available. Competitive salary, generous benefits and a comprehensive retirement program. For more information, send CV with cover letter to: Diane Butler, The Permanente Medical Group, Inc., Physician Recruitment, 1814 Franklin, 4th Floor, Oakland, CA 94612. EOE.

Radiation Safety

Full-time position available at Department of Veterans Affairs Medical Center, Huntington, WV. Applicant with M.A. or PhD in Radiation Physics is desirable. Responsibilities include Radiation Safety Program in Nuclear Medicine, Radiology and Research and the implementation of NRC and State regulations. Salary range: $40,298-62,293 per annum with excellent benefits package. Huntington, WV is a family oriented university community and enjoys a moderate four-season climate. Located at the junction of Ohio, Kentucky and West Virginia, we have a beautiful natural setting on the Ohio River. The area offers the lowest crime rate in the nation, good public and private schools and recreation activities to meet most family life styles. If interested, please call or send CV to: Joseph A. Pellecchia, MD, Chief of Staff, VA Medical Center, 1540 Spring Valley Drive, Huntington, WV 25704; Tel# (304) 429-6755, Ext. 2275. Equal Opportunity Employer.

Radiology

University of Caliifornia, Irvine, Department of Radiological Sciences is recruiting a faculty position for an individual who will be half-time in Nuclear Medicine and is Board certified in Nuclear Medicine, and half-time in the General Radiology area. Responsibilities include clinical service, medical student and resident teaching. The appointment will be at the level of Assistant or Associate Clinical Professor. Applicants should possess a California license and certification by the American Board of Radiology. Salary is commensurate with rank and experience. Please forward curriculum vitae to M. Joyce Pais, MD, Chairman's Office, Department of Radiological Sciences, University of California Irvine Medical Center, 101 City Drive South, Route 140, Orange, CA 92668. The University of California is an Affirmative Action/Equal Opportunities employer.

Resident

Two and three-year Nuclear Medicine Residencies are available at St. Luke's Medical Center, Milwaukee, WI. St. Luke's is a 600-bed general and acute care community hospital, and is one of the largest cardiac care centers in the U.S. The program gives the resident very strong training in nuclear cardiology, SPECT imaging, and general nuclear medicine. Instrumentation is modern and includes one triple head SPECT camera, one dual head SPECT camera, five single head SPECT cameras, one dual head whole body camera, one LFOV camera, one mobile gamma camera, and a large networked nuclear medicine computer system. Well over 11,000 procedures are performed annually. Staff includes 2 full-time double boarded ABNM certified physicians, 1 medical physicist, 1 nuclear pharmacist, 1 programmer and a technical staff of 16. The residency is structured around a strong teaching program in the basic sciences and clinical nuclear medicine. Call is shared among multiple individuals, residents are always backed up by staff, and adequate time is available for reading and research. Residents are required to write one paper per year. Address applications and inquiries to Dr. David Yuille, Director of Nuclear Medicine Residency, St. Luke's Medical Center, 2900 W. Oklahoma Avenue, Milwaukee, WI 53215, (414)649-6418.

NUCLEAR MEDICINE RESIDENCY-July 1994: Loyola University Medical Center/Hines VA Hospital has three openings for first year Nuclear Medicine residents leading to a certification by the American Board of Nuclear Medicine. Cardiac, SPECT, Computer Processing, University and VA Hospitals. Prerequisite: 2 years ACGME-approved residency program. Send CV to Gary L. Dillehay, MD, Section of Nuclear Medicine, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois 60153. Phone (708)216-3777. An Equal Opportunity/Affirmative Action Employer.

Positions Wanted

Physician

ABNM cert., ABIM elig., PHYSICIAN (former PhD chemist, recently Med Director for large drug company): seeks full-time clin/acad position at a university-based med center (with PET/SPECT, animal lab, and grad chem/biochem depart) to design new Rx/Dx agents. Reply to Box 201, The Society of Nuclear Medicine, 136 Madison Ave., New York, NY 10016.

ABNM-certified MD seeks full or part-time position. Extensive experience including SPECT, Cardiac, Thyroid. Reply to: Box 202, The Society of Nuclear Medicine, 136 Madison Ave., New York, NY 10016.

Environment, Safety & Health Manager

Argonne National Laboratory is currently seeking a Section Head (Manager) to provide leadership for internal and external personnel radiation dosimetry, environmental/occupational radiochemistry and industrial hygiene chemistry in the Environment, Safety and Health Division of Argonne National Laboratory. Argonne is an advanced multi-disciplinary R&D facility operated by the University of Chicago for the U.S. Department of Energy.

Qualified candidates must have prior experience in conducting/managing an in-house personnel dosimetry program(s) and extensive experience working with dosimetry instrumentation typical of a large medical or R&D institution. Management experience with strong communications, team-building and leadserhip skills is essential; a flexible, adaptable management style in an individual with the ability to motivate others is required. Substantial experience in interpreting and implementing various federal and state regulatory requirements in the areas of radiation control, environmental compliance and control of radioactive waste is preferred. A solid background in both technical and administrative computing applications is desirable.

A graduate degree in physics, health physics or chemistry or other technical discipline and 10-15 years experience is required. A PhD and board certification as a health or medical physicist is preferred. The successful candidate will manage a staff of approximately 30 people and will play an active role in an ESH division of approximately 170.

At Argonne, you'll find an environment that encourages both personal and professional career growth as well as excellent compensation and benefits. We welcome applications from candidates who can contribute to our EEO/Affirmative Action goals. For consideration, please send your resumé and salary history to: Susan M. Walker, ESH-107984-5J, Employment and Placement, Argonne National Laboratory, 9700 South Cass Ave., Argonne, IL 60439. Telecommunications Device for the Deaf-(708) 252-7722. Argonne is an equal opportunity/affirmative action employer.

Argonne National Laboratory

NUCLEAR MEDICINE RESIDENCY

The University of Tennessee Medical Center at Knoxville offers a two-year residency program of extensive practical and didactic training which covers all diagnostic and therapeutic uses of radiotracers in the practice of nuclear medicine. Emphasis is placed on nuclear cardiology and on providing residents with a unique opportunity to become familiar with clinical PET applications. Participation in specific research projects is encouraged.

The University of Tennessee Medical Center at Knoxville is a 600-bed acute-care hospital and the regional referral center for East Tennessee. Totally new and encompassing 7,500 square feet, the Nuclear Medicine facility is equipped with four SPECT scanners in addition to four stationary and two mobile gamma cameras. The 3,600 square feet PET Center houses a medical cyclotron, radiochemistry laboratory, and two multi-slice PET scanners. The entire facility is networked into a large computer Image Processing Laboratory. Over 6,000 scintigraphic studies and 1,000 PET examinations were performed in these facilities during 1993.

Knoxville and the East Tennessee area offer exceptional lifestyle advantages. These include year-round recreation, lakes and mountains, affordable housing, a stable economy, and a low cost of living.

Applicants must have at least one year of ACGME-approved training in internal medicine, pediatrics, pathology or radiology prior to beginning the Nuclear Medicine Residency. Candidates should send a letter of application and a curriculum vitae to:

K.F. Hubner, M.D.
Director, Nuclear Medicine Residency Program
The University of Tennessee Medical Center at Knoxville
1924 Alcoa Highway • Knoxville, TN 37920

The University of Tennessee Medical Center at Knoxville is an EEO/AA/TITLE IX/SECTION 504/ADA Employer.

THE UNIVERSITY OF TENNESSEE
Medical Center at Knoxville

CEDARS-SINAI MEDICAL CENTER

NUCLEAR MEDICINE RESIDENCY

Cedars-Sinai Medical Center, a 1000 bed, full service, acute, tertiary care hospital affiliated with UCLA School of Medicine, is seeking two residents for our ACGME approved program in Nuclear Medicine. Our dynamic department includes 5 multi-detector SPECT systems, 3 single detector systems and 2 multi-crystal cameras, and offers a full range of nuclear medicine services. Staffing includes 4 nuclear medicine physicians, a radiopharmicist and 2 physicists. The program emphasizes teaching, research, and a diversified clinical experience. Major research programs exist in nuclear cardiology, nuclear oncology, as well as pulmonary and endocrine medicine. If you enjoy working in a busy, progressive environment with a challenge for personal growth, please contact:

Daniel S. Berman, M.D.
Co-director, Department of Imaging
Director, Nuclear Medicine Residency Program
Cedars-Sinai Medical Center
8700 Beverly Boulevard, Room 5413
Los Angeles, California 90048

-An Equal Opportunity Employer-

ACGME Accredited Two-Year Nuclear Medicine Residency

This is an accredited Nuclear Medicine Residency at one of the country's most prestigious private institutions. The faculty to resident ratio is 1:1 with state-of-the-art equipment including one dual head whole body planar scanner, two triple head SPECT scanners, one dual head SPECT scanner, one single head SPECT scanner, two multi-crystal cardiac first pass cameras, and a state-of-the-art Positron Emission Tomography scanner and cyclotron. The experience will include, but will not be limited to, cardiac and non-cardiac clinical nuclear medicine, radiopharmacy, radio-immunoassay, nuclear physics, and exposure and training in Magnetic Resonance Imaging and potentially spectroscopy. Extensive lectures and teaching conferences are pre-planned. This two year residency is accredited by the ACGME.

Department has an extremely active clinical service with between 40-50 exams per day performed on the state-of-the-art equipment as described above. Extensive academic support, extensive library resources, and the opportunity for basic and clinical research exists. Salary and fringe benefits are highly competitive. Applications for July 1, 1994 are due by May 15, 1994 and applications for July 1, 1995 are due by January 1, 1995. To receive more information about our accredited Nuclear Medicine Residency, please contact: Stephen J. Pomeranz, M.D., Director of Advanced Imaging, Nuclear Medicine and Metabolic Imaging at The Christ Hospital, Department of Nuclear Medicine and Metabolic Imaging, 2139 Auburn Ave., Cincinnati, OH 45219, (513) 369-1146.

The Christ Hospital is an affirmative action, equal opportunity employer.

JNM

DIRECT RESPONSE

Advertisers for February 1994

The *Journal* is testing a new method to enable you to get information on a more timely basis from our advertisers.

Listed below are the companies that have advertised in this issue, as well as those that have been mentioned in the New Products section. simply circle the numbers of those companies you are interested in, fill out the form, and mail or FAX it to The Society of Nuclear Medicine, Marketing Dept., 136 Madison Ave., New York, NY 10016. FAX: (212) 545-0221. We will send it to the advertiser.
Deadline: **April 15, 1994**

7 AccuSync, Inc
Milford, CT
(203) 877-1610
Page 7A

23 Capintec, Inc.
Ramsey, NJ
(800) 631-3826
Page 2A

32 Diversified Diagnostic Products, Inc.
Houston, TX
(713) 955-5323
Page 27A

34 Du Pont Company
No. Billerica, MA
(800) 343-7851
Page 15A-16A

107 Knoll Pharmaceuticals
Whippany, NJ
(800) 833-3533
Pages 9A-12A

126 Medi-Physics, Inc.
Arlington Heights, IL
(708) 593-6300
Pages 21A-24A

181 Siemens Medical Systems, Inc.
Hoffman Estates, IL
(708) 304-7252
Inside Front Cover, Back Cover

217 Willard Industries, Inc
Charlotte, NC
(800) 476-1230
Page 29A

A **SNM Meetings**
Pages 8A, 30A,

B **SNM Membership Information**

C **SNM Book Order Information**

From:

Your Name: _____ Title: _____

Institution: _____ Dept: _____

Address: _____

City: _____ State: _____ Zip: _____

Phone: _____ FAX: _____

Primary Specialty: _____ Secondary Specialty: _____

Circle One Answer In Each Category

Employer
1. Hospital
   a. 500 patients plus
   b. 300-499 patients
   c. 200-299 patients
   d. 100-199 patients
2. Private Clinic
3. R&D Commercial
4. University
5. Government
6. Other _____

Purchase Authority
1. Recommend
2. Specify
3. Purchase

Reason for Inquiry
1. Immediate Purchase
2. General Information
3. Budgeting Information

SNM Member
1. Yes
2. No

SNM Subscriber
1. Yes
2. No

Defining the Field . . .
New Titles in Technology from The Society of Nuclear Medicine

Recently published books from SNM provide authoritative, up-to-date discussion of key subjects in nuclear medicine technology. Adding to your professional library has never been easier—Simply call the toll-free number below for fast, efficient service.



CLINICAL COMPUTERS IN NUCLEAR MEDICINE
Katherine L. Rowell

$35 members/$50 nonmembers. A companion text to *Computers in Nuclear Medicine,* this survey traces the evolution of nuclear medicine computer technology. An essential guide for staff operating computers in clinical settings.



COMPUTERS IN NUCLEAR MEDICINE: A PRACTICAL APPROACH
Kai Lee

$30 members/$45 nonmembers.This illustrated guide explains both how computers work and how processing techniques obtain diagnostic information from radionuclide images.



A PATIENT'S GUIDE TO NUCLEAR MEDICINE, REVISED EDITION

Pamphlet, $0.40 (100 copies, minimum order). This popular pamphlet explains nuclear medicine procedures in clear, concise language, helping to allay patient anxieties. Format includes common questions and answers; step-by-step descriptions of procedures; photographs showing patients undergoing imaging. An update of the highly successful patient pamphlet in use since 1983.



REVIEW OF NUCLEAR MEDICINE TECHNOLOGY
Ann M. Steves

$30 members/$45 nonmembers.Both an overview of the latest techniques in nuclear medicine technology as well as an authoritative study guide, this practical handbook is a valuable addition to the libraries of students and specialists alike.



CURRICULUM GUIDE FOR NUCLEAR MEDICINE TECHNOLOGISTS, 2ND EDITION,
Wanda M. Mundy and Gregory Passmore

$15.95 members/$19.95 nonmembers. An invaluable tool for educators and program administrators, this new edition of the *Curriculum Guide* also serves continuing-education aims for those already working in the field.Thoroughly revised in response to latest advances in nuclear medicine technology.

TO ORDER, CALL TOLL-FREE, BOOKMASTERS, INC.1-800-247-6553 (Outside the U.S. 419-281-1802)

SIEMENS

Announcing

The Industry's First 3-Year Crystal Warranty

We understand why others haven't made this offer . . .
If we used their crystals, we wouldn't either!





Albert Einstein
Great Minds and Nuclear Medicine
Second in a series

Let's face it, in today's cost conscious health care environment good medicine means being a "best value" provider.

At Siemens this means providing for your technical requirements as well as protecting your bottom line.

That's why we're proud to introduce this exclusive 3-Year Crystal Warranty.

Our patented double-seal detector assembly process prevents yellowing and hydration. So you won't have to pay to replace one of the most expensive components in any of our new gamma cameras.

Just another innovation from Siemens Nuclear Medicine Group, where all systems are Economically Engineered for managed care.

Siemens Medical Systems
Nuclear Medicine Group
2501 Barrington Road
Hoffman Estates, IL 60195
Telephone: 708-304-7700

Siemens...
technology in caring hands